Immunization of Small Cell Lung Cancer Patients With a Pentavalent Vaccine Composed of KLH-conjugates of GD2L, GD3L, Globo H, Fucosyl GM1, and N-Propionylated Polysialic Acid

Trial Profile

Immunization of Small Cell Lung Cancer Patients With a Pentavalent Vaccine Composed of KLH-conjugates of GD2L, GD3L, Globo H, Fucosyl GM1, and N-Propionylated Polysialic Acid

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Jan 2016

At a glance

  • Drugs Small-cell-lung-cancer-vaccine (Primary) ; Carboplatin; Cisplatin; Etoposide; OPT 821
  • Indications Small cell lung cancer
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 22 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 29 Apr 2015 Planned End Date changed from 1 May 2015 to 1 May 2016 as reported by ClinicalTrials.gov record.
    • 29 Apr 2015 Planned primary completion date changed from 1 May 2015 to 1 May 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top